Jamie Koprivnikar, MD

Articles

Key Takeaways From Iopofosine I 131 in Previously Treated Patients With Waldenstrom Macroglobulinemia (WM) in the CLOVER-WaM Trial

May 1st 2025

Panelists discuss how iopofosine I 131 demonstrated efficacy and safety in previously treated patients with Waldenstrom macroglobulinemia (WM) in the CLOVER-WaM study, potentially influencing the broader treatment paradigm by introducing a novel targeted radiopharmaceutical approach and shaping future research toward optimizing combination therapies and long-term outcomes.

Overview of the 5-Year Follow-Up Analysis From ZUMA-5: A Phase 2 Trial of Axi-Cel in R/R Indolent NHL

May 1st 2025

Panelists discuss how the 5-year follow-up data from the ZUMA-5 trial demonstrate sustained efficacy and durable remission of axicabtagene ciloleucel in patients with relapsed/refractory (R/R) indolent non-Hodgkin lymphoma (iNHL), potentially signaling a paradigm shift toward considering chimeric antigen receptor (CAR) T-cell therapy as a more prominent early-line treatment option for these challenging lymphoma subtypes.

Future of Bispecifics and CAR T in R/R MM

April 24th 2025

Panelists discuss how the preliminary results from the IMMagine-1 trial (ASH 2024, abstract #1031) on anitocabtagene autoleucel highlight the evolving role of bispecifics and chimeric antigen receptor (CAR) T-cell therapies in the treatment landscape for relapsed/refractory multiple myeloma (R/R MM).

Choosing Between Bispecifics and CAR T: Real-World Implications in R/R MM

April 24th 2025

Panelists discuss how the preliminary results from the iMMagine-1 trial on anitocabtagene autoleucel (ASH 2024, abstract #1031) inform the real-world decision-making between bispecifics and chimeric antigen receptor (CAR) T-cell therapy for patients with relapsed/refractory multiple myeloma (R/R MM).

Overview of iMMagine-1 Trial: Phase 2 Registrational Study of Anitocabtagene Autoleucel for the Treatment of R/R MM

April 17th 2025

Panelists discuss how the preliminary results from the iMMagine-1 trial of anitocabtagene autoleucel in relapsed/refractory multiple myeloma (R/R MM) highlight promising efficacy in triple-class and penta-class refractory patients, potentially reshaping treatment strategies and challenging existing paradigms in managing heavily pretreated myeloma.

Application of Real-World Evidence in Selecting CAR T in R/R MM

April 17th 2025

Panelists discuss how real-world comparative analyses reveal nuanced differences in the efficacy and safety profiles of ciltacabtagene autoleucel and idecabtagene vicleucel among patients with relapsed/refractory multiple myeloma (R/R MM), highlighting the critical importance of translating clinical trial data into practical treatment strategies.

Insights From the Comparative Efficacy and Safety of Ciltacabtagene Autoleucel and Idecabtagene Vicleucel in Real-World Relapsed/Refractory Multiple Myeloma: A Retrospective Intention-to-Treat Analysis

April 10th 2025

Panelists discuss how real-world analyses of chimeric antigen receptor (CAR) T-cell therapies in relapsed/refractory multiple myeloma (R/R MM), as presented in abstract #2408 by Amoozgar et al at ASH 2024, provide insights into the comparative efficacy and safety of ciltacabtagene autoleucel and idecabtagene vicleucel, highlighting differences between real-world outcomes and clinical trial results.

Welcome to This OncLive Peer Exchange: Highlighting Key Abstracts From ASH 2024

April 10th 2025

Panelists discuss how key data from ASH 2024 impact current approaches to treating hematologic malignancies, with a focus on multiple myeloma, lymphoma, and leukemia.

Dr. Koprivnikar Discusses FLT3 Inhibitors in Hematologic Malignancies

January 31st 2018

Jamie Koprivnikar, MD, medical oncologist, John Theurer Cancer Center, discusses FLT3 inhibitors in the treatment of hematologic malignancies.